Helicos' Q3 Loss Rises 15 Percent, Expects Orders at Low End of Guidance | GenomeWeb
This article has been updated to include additional comments from Helicos' conference call this morning.
 
NEW YORK (GenomeWeb News) – Helicos BioSciences today reported a 15 percent increase in its third-quarter net loss and a dip in grant revenue as it continues to perform validation studies of its flagship Helicos Genetic Analysis Platform in house. It also revised its guidance downward on orders for the system for the remainder of this year, citing economic conditions.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.